Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
In an effort to prevent surgery in selected patients with esophageal cancer, the SANO-2 study
offers active surveillance to patients with clinically complete response (cCR) after
neoadjuvant chemoradiation (nCRT). Some of these patients will never develop locoregional
and/or distant recurrence of disease (persistent cCR). However, two-thirds of the patients
that undergo active surveillance still get disease recurrence. This can be locoregional
regrowth or distant metastases. To increase the efficacy of active surveillance (reduce the
proportion of patients that need surgery) and improve survival, effective systemic
maintenance therapy is needed. The CheckMate 577 randomized, placebo controlled, clinical
trial showed that Nivolumab increases disease free survival in patients after nCRT and
esophagectomy.
Objective: To assess the efficacy of nivolumab during active surveillance in patients with
cCR after neoadjuvant chemoradiation for esophageal cancer